NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the nea
CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR,  to try to improve human health.
Two investing influencers have expressed opposite takes on how investors should play the current market. Michael Burry, of The Big Short fame, is no stranger to issuing ominous warnings for investors.
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editin
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

CRISPR Therapeutics Stock: Bull vs. Bear

10:07am, Thursday, 19'th Jan 2023
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r
CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland

5 Potentially Explosive Stocks to Buy in 2023

05:30am, Friday, 13'th Jan 2023
These stocks all dropped in the double digits last year. But their future prospects are brilliant.
These two companies are in very different situations but could generate significant returns for investors.
CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
These biotechnology stocks are pushing ahead with promising innovations.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE